Document is current
Any future updates will be listed below
-
Authors
Dam, Tien https://orcid.org/0000-0002-7786-5825
Yang, Lili https://orcid.org/0000-0002-6975-3145
Gillis, Colin
Li, Yumeng
O’Gorman, John https://orcid.org/0000-0001-6549-4038
Kolb, Barbara
Boxer, Adam L. https://orcid.org/0000-0002-1215-5064
Golbe, Lawrence
Budd Haeberlein, Samantha https://orcid.org/0000-0002-4824-646X
,
- License Information
-
More Information
Article History
Received: 11 January 2023
Accepted: 11 December 2024
First Online: 6 January 2025
Competing interests
: Tien Dam, Lili Yang, Colin Gillis, Yumeng Li, Barbara Kolb, and Samantha Budd Haeberlein are former employees of and may hold stock/stock options in Biogen. John O’Gorman is an employee of and may hold stock in Biogen. Adam Boxer receives research support from the National Institutes of Health, Tau Research Consortium, Association for Frontotemporal Degeneration, Bluefield Project to Cure Frontotemporal Dementia, Alzheimer’s Drug Discovery Foundation, Alzheimer’s Association, Biogen, Eisai, and Regeneron and has served as a consultant for AGTC, Alector, Arkuda, Arvinas, AviadoBio, AZTherapeutics, Boehringer Ingelheim, GSK, Humana, Life Edit Therapeutics, Oligomerix, Roche, TrueBinding, and Wave. Lawrence Golbe has received research support from Biogen, travel support from CurePSP, and Consultant fees from AI Therapeutics, Amylyx, Apellis, Aprinoia, Ferrer, Mitochon, Roche, and UCB. These analyses were funded by Biogen (Cambridge, MA, USA). The 4 Repeat Tauopathy Imaging Initiative is funded by National Institutes of Health grant R01AG038791.
